Loss, mutation and deregulation of L3MBTL4 in breast cancers

Archive ouverte

Addou-Klouche, Lynda | Adélaïde, José | Finetti, Pascal | Cervera, Nathalie | Ferrari, Anthony | Bekhouche, Ismahane | Sircoulomb, Fabrice | Sotiriou, Christos | Viens, Patrice | Moulessehoul, Soraya | Bertucci, François | Birnbaum, Daniel | Chaffanet, Max

Edité par CCSD ; BioMed Central -

International audience. Abstract Background Many alterations are involved in mammary oncogenesis, including amplifications of oncogenes and losses of tumor suppressor genes (TSG). Losses may affect almost all chromosome arms and many TSGs remain to be identified. Results We studied 307 primary breast tumors and 47 breast cancer cell lines by high resolution array comparative genomic hybridization (aCGH). We identified a region on 18p11.31 lost in about 20% of the tumors and 40% of the cell lines. The minimal common region of loss (Chr18:6,366,938-6,375,929 bp) targeted the L3MBTL4 gene. This gene was also targeted by breakage in one tumor and in two cell lines. We studied the exon sequence of L3MBTL4 in 180 primary tumor samples and 47 cell lines and found six missense and one nonsense heterozygous mutations. Compared with normal breast tissue, L3MBTL4 mRNA expression was downregulated in 73% of the tumors notably in luminal, ERBB2 and normal-like subtypes. Losses of the 18p11 region were associated with low L3MBTL4 expression level. Integrated analysis combining genome and gene expression profiles of the same tumors pointed to 14 other potential 18p TSG candidates. Downregulated expression of ZFP161, PPP4R1 and YES1 was correlated with luminal B molecular subtype. Low ZFP161 gene expression was associated with adverse clinical outcome. Conclusion We have identified L3MBTL4 as a potential TSG of chromosome arm 18p. The gene is targeted by deletion, breakage and mutations and its mRNA is downregulated in breast tumors. Additional 18p TSG candidates might explain the aggressive phenotype associated with the loss of 18p in breast tumors.

Consulter en ligne

Suggestions

Du même auteur

Genome profiling of ERBB2-amplified breast cancers

Archive ouverte | Sircoulomb, Fabrice | CCSD

International audience. Abstract Background Around 20% of breast cancers (BC) show ERBB2 gene amplification and overexpression of the ERBB2 tyrosine kinase receptor. They are associated with a poor prognosis but can...

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer

Archive ouverte | Sircoulomb, Fabrice | CCSD

International audience. Luminal B breast cancers represent a fraction of oestrogen receptor (ER)-positive tumours associated with poor recurrence-free and disease-specific survival in all adjuvant systemic treatment...

Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling

Archive ouverte | Cornen, Stéphanie | CCSD

International audience. Breast cancers (BCs) of the luminal B subtype are estrogen receptor-positive (ER+), highly proliferative, resistant to standard therapies and have a poor prognosis. To better understand this ...

Chargement des enrichissements...